OncoExTra™ test
Don't miss half the genomic story. Personalize your advanced cancer care with ultra-comprehensive genomic profiling.
Interrogating both DNA and RNA, the OncoExTra test provides ultra-comprehensive genomic profiling that thoroughly detects clinically actionable mutations and fusions.1
It delivers the all-encompassing genomic insights of whole-exome (DNA) and whole-transcriptome (RNA) sequencing, highlighting key information that is critical to personalized cancer care.
The full genomic story requires more than DNA alone
The OncoExTra report:
putting a spotlight on what matters most
The easy-to-interpret report highlights the most actionable insights first for timely, shared decision-making:
- Mutations and fusions associated with FDA-approved therapies deliver a comprehensive genomic picture*
- Immuno-oncology signatures (TMB/MSI) support personalized therapy selection
- Clinical trial options to help inform next steps
*The OncoExTra test is not an FDA-cleared or -approved IVD device or companion diagnostic for the referenced biomarkers and FDA-approved therapies.
of cancer morbidity occurs in tumors driven by translocations and gene fusions, according to one estimate.2 Many of these variants are actionable and may be missed by DNA panel-based tests.3,4
Uncover more variants. Find more useful targets.
- Ultra-comprehensive genomic profiling interrogates both tumor DNA and RNA1
- Broad and deep sequencing coverage accurately detects mutations, rare fusions, and transcript variants1
- Patient-matched tumor-normal sequencing uncovers benign mutations1
- Optional immunohistochemical (IHC) panels and single stains provide an added level of detail
The OncoExTra test may be right for
your patient whose cancer is:
 Advanced or metastatic |
Rare |
| Unresponsive to treatment or recurrent |
Aggressive |
Fax your order
MSI, microsatellite instability; TMB, tumor mutational burden.
-
References